-
Pfizer Halts Development of Sisunatovir, an RSV Antiviral, After Phase II/III Trials
•
U.S. pharmaceutical giant Pfizer (NYSE: PFE) has decided to discontinue the development of sisunatovir, an antiviral drug for respiratory syncytial virus (RSV), following challenges including drug-drug interactions with antacids. The drug had reached the Phase II/III trial stage, and the decision will see two trials discontinued, according to Endpoints News.…
-
Blue Shield Biotech Faces Bankruptcy Proceedings After Missing Debt Payments
•
The Nanjing Qixia District People’s Court has accepted a bankruptcy liquidation case for Blue Shield Biotech, a China-based pharmaceutical company specializing in tumor drug development. The move comes after Blue Shield Biotech failed to meet its debt obligations. As of April 9, 2024, the company’s total employee debt stood at…
-
LianBio to Wind Down Operations Amid Market Challenges, Announces Special Dividend
•
LianBio (OTCMKTS: LIANY), one of China’s prominent biotechnology firms, has announced plans to wind down its operations following a strategic review in light of challenging biotech market conditions. This decision initiates a gradual process that includes the divestiture of remaining pipeline assets, delisting from NASDAQ, and deregistration as a corporate…
-
LianBio Board Turns Down Concentra Biosciences Buyout Offer
•
China-based LianBio (OTCMKTS: LIANY) has announced that its board of directors has unanimously decided not to proceed with a buyout proposal from Concentra Biosciences LLC, deeming the offer not to be in the best interests of shareholders. In early December, Concentra Biosciences LLC, a company under the control of private…
-
Concentra Biosciences Targets China-Based Biotech LianBio in Unsolicited Takeover Bid
•
LianBio (OTCMKTS: LIANY), a China-based biotech firm, has become the target of an unsolicited takeover bid by Concentra Biosciences LLC, a company controlled by private equity fund Tang Capital Partners LP. The cash offer is set at USD 4.30 per share for 100% of LianBio’s equity, a significant premium that…
-
LianBio Secures Clinical Supply Agreement with AstraZeneca for SHP2 Inhibitor Trial
•
Sino-US biotech firm LianBio (OTCMKTS: LIANY) has announced the signing of a clinical supply agreement with UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN). The agreement facilitates LianBio’s plan to test the combination of its pipeline SHP2 inhibitor, BBP-398, with AstraZeneca’s Tagrisso (osimertinib) in a Phase I clinical trial for patients…
-
LianBio Appoints Pascal Qian as COO in Anticipation of Mavacamten Market Launch
•
China-based biotech firm LianBio (OTCMKTS: LIANY) has announced the promotion of its current China General Manager (GM), Pascal Qian, to the position of Chief Commercial Officer (COO). This strategic move comes as LianBio prepares for the potential market launch of mavacamten, a first-in-class molecule for the treatment of obstructive hypertrophic…
-
LianBio’s TP-03 Begins Phase III Trial for Demodectic Blepharitis in China
•
Shanghai-based biopharmaceutical company LianBio (OTCMKTS: LIANY) has announced the first patient dosing in a Phase III LIBRA study for its TP-03, targeting demodectic blepharitis in Chinese patients. This marks a significant step forward in addressing a prevalent eye disease in the region. Understanding Demodectic BlepharitisDemodectic blepharitis is a common eye…
-
LianBio Cancels Phase III Trial for Truseltiq in China Amid Global Halt
•
China-based LianBio (OTCMKTS: LIANY) revealed in an SEC filing that it is canceling work on a Phase III trial in China for Truseltiq (infigratinib). The decision follows an announcement by BridgeBio Pharma Inc. (NASDAQ: BBIO), the drug’s discoverer, that the ongoing global Phase III PROOF-301 trial is being closed. This…
-
LianBio Completes Enrollment for Mavacamten Phase III Trial in oHCM
•
China-based biotech LianBio (OTCMKTS: LIANY) announced that enrollment has been completed in the Phase III EXPLORER-CN clinical trial, assessing mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Drug BackgroundMavacamten, discovered by MyoKardia Inc. (Nasdaq: MYOK), is a first-in-class small-molecule drug that reversibly binds to myosin. It targets the…
